Efficacy of a Xanthan-based Chlorhexidine Gel in the Treatment of Peri-implant Mucositis
1 other identifier
interventional
182
1 country
1
Brief Summary
The peri-implant mucositis is an inflammatory and reversible lesion that surrounds the peri-implant mucosa without loss of supporting bone, clinically characterized by bleeding on gentle probing. It has been estimated that it affects approximately 21% to 88% of individuals and 9% to 51% of implant sites, with prevalences of 47% and 29%, respectively. Experimental clinical researches show that peri-implant mucositis can be reversed if proper biofilm management is maintained. Prevention and regression of inflammation around the implant can be achieved through proper oral hygiene and an effective supportive care protocol, which may include regular clinical check-ups, radiographic assessments, oral hygiene instructions and professional mechanical plaque removal (PMPR). Therefore, adjunctive measures such as self-administration of oral rinse antiseptics (i.e. chlorhexidine) may be considered. For examples, the use of a chlorhexidine-based gel in combination with xanthan (XanCHX), in addition to PMPR has demonstrated clinical improvements in the treatment of periodontitis. The aim of the present study was to investigate the potential benefits of XanCHX gel in adjunction to PMPR in patients affected by peri-implant mucositis, promoting a complete healing of the affected tissues.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 14, 2025
CompletedFirst Submitted
Initial submission to the registry
June 17, 2025
CompletedFirst Posted
Study publicly available on registry
July 2, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2025
CompletedApril 29, 2026
June 1, 2025
7 months
June 17, 2025
April 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Bleeding on Probing
Presence or absence of gingival bleeding within 30 seconds after probing
From baseline until the end of the study (6 months)
Secondary Outcomes (5)
Probing pocket depth
From the baseline until the end of the study (6 months)
Plaque index
From baseline until the end of the study (6 months)
Gingival recession
From the baseline until the end of the study (6 months)
Keratinized gingiva
From the baseline until the end of the study (6 months)
Clinical attachment level
From the baseline until the end of the study (6 months)
Study Arms (2)
Professional mechanical plaque removal with xanthan-chlorhexidine based gel
EXPERIMENTALAt baseline, after recording clinical parameters, patients received oral hygiene instruction and underwent periodontal debridement alternating ultrasonic with manual instruments, followed by the use of air-abrasive devices with 25-micron glycine powder and a supragingival tip Subsequently, the clinician cleaned and dried the site using compressed air and applied the XanCHX gel on the implant sites assigned to the test group, positioning the blunt needle at the bottom of the pocket and gently extruding the product while moving it out of the site. Finally, the patient was instructed not to drink or rinse for the following hour. At each time-step, clinical assessments were recorded after the reinforcement in oral hygiene instruction and professional implant hygiene using rubber cup and polishing paste.
Professional mechanical plaque removal alone
NO INTERVENTIONAt baseline, after recording clinical parameters, patients received oral hygiene instruction and underwent periodontal debridement alternating ultrasonic with manual instruments, followed by the use of air-abrasive devices with 25-micron glycine powder and a supragingival tip. At each time-step, clinical assessments were recorded after the reinforcement in oral hygiene instruction and professional implant hygiene using rubber cup and polishing paste.
Interventions
The chlorhexidine and xanthan-based gel contains 0.5% chlorhexidine digluconate, 1% chlorhexidine dihydrochloride, and 0.5% xanthan gel. Xanthan is a polymer that creates a three-dimensional, pseudo-plastic network with water, forming a stable gel that allows a slow and prolonged release of chlorhexidine, allowing effectiveness for about 30 days. Chlorhexidine digluconate is released immediately upon application, whereas Chlorhexidine dihydrochloride is gradually delivered the following days, providing bacteriostatic and bactericidal effects for up to two weeks, helping the prevention of recolonization of treated site. The clinician cleaned and dried the implant site using compressed air and applied the XanCHX gel on the implant sites assigned to the test group, positioning the blunt needle at the bottom of the pocket and gently extruding the product while moving it out of the site. Finally, the patient was instructed not to drink or rinse for the following hour.
Eligibility Criteria
You may qualify if:
- presence of two or more peri-implant mucositis sites (e.g. presence of bleeding and/or suppuration on probing with no bone loss evident on radiographs);
- implant-supported fixed restorations inserted at least 6 months before patient enrollment
You may not qualify if:
- radiation therapy in the head and neck therapy or long-term corticosteroid treatments;
- use of systemic antibiotics for more than 6 months;
- diagnosis of not plaque-associated inflammatory diseases (e.g., Oral Lichen Planus);
- pregnant or breastfeeding mother;
- untreated peri-implantitis;
- oral rehabilitation with full-arch prostheses;
- allergy to chlorhexidine and/or other components contained in the gel.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
AOU Città della Salute e della Scienza
Torino, Italy, 10126, Italy
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dental Hygienist Registered (RDH)
Study Record Dates
First Submitted
June 17, 2025
First Posted
July 2, 2025
Study Start
February 14, 2025
Primary Completion
August 30, 2025
Study Completion
September 1, 2025
Last Updated
April 29, 2026
Record last verified: 2025-06